Wenwen Luo1, Deyi Zhang1, Shumin Ma1, Chenyao Wang1, Qian Zhang1, Huafei Wang1, Kunyan He2, Zhixue Liu1. 1. Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China. 2. Key Laboratory of Systems Biomedicine Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Abstract
BACKGROUND: Cancer stem cells (CSCs) are responsible for tumor relapse after chemotherapy and radiotherapy in non-small cell lung cancer (NSCLC). The aim of this study is to explore the profile and role of microRNA (miRNA) in CSC of NSCLC. MATERIALS AND METHODS: We studied the expression of stem cell marker in side population cells and serum-free cultured spheres of NSCLC. We identified that CD133+ CD34- cells are NSCLC stem cell. We isolated CD133+ CD34- cells and CD133- CD34+ cells with MicroBead Kit. We verified that H1650 CD133+ CD34- cells have CSC characteristics with doxorubicin, radiation, and xenograft. We studied miRNA expression profile in H1650 and HCC827 CD133+ CD34- cells with microarray analysis. We detected proliferation, migration, and invasion with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch test, and Transwell chamber invasion assay, respectively. RESULTS: CD133 and CD34 are CSC markers in H1650. We demonstrated that H1650 CD133+ CD34- cells have CSC characteristics and found that miR-27a was highly expressed in H1650 CD133+ CD34- cells. In addition, we showed that miR-27a regulates proliferation, migration, and invasion in H1650 cell line and demonstrated that miR-27a expression was positively related to epidermal growth factor receptor in NSCLC cell lines. CONCLUSIONS: CD133+ CD34- is a CSC marker in H1650. miR-27a is highly expressed in H1650 CSCs and regulates cancer development in H1650. miR-27a may be a potential target for NSCLC therapy.
BACKGROUND: Cancer stem cells (CSCs) are responsible for tumor relapse after chemotherapy and radiotherapy in non-small cell lung cancer (NSCLC). The aim of this study is to explore the profile and role of microRNA (miRNA) in CSC of NSCLC. MATERIALS AND METHODS: We studied the expression of stem cell marker in side population cells and serum-free cultured spheres of NSCLC. We identified that CD133+ CD34- cells are NSCLC stem cell. We isolated CD133+ CD34- cells and CD133- CD34+ cells with MicroBead Kit. We verified that H1650 CD133+ CD34- cells have CSC characteristics with doxorubicin, radiation, and xenograft. We studied miRNA expression profile in H1650 and HCC827 CD133+ CD34- cells with microarray analysis. We detected proliferation, migration, and invasion with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch test, and Transwell chamber invasion assay, respectively. RESULTS: CD133 and CD34 are CSC markers in H1650. We demonstrated that H1650 CD133+ CD34- cells have CSC characteristics and found that miR-27a was highly expressed in H1650 CD133+ CD34- cells. In addition, we showed that miR-27a regulates proliferation, migration, and invasion in H1650 cell line and demonstrated that miR-27a expression was positively related to epidermal growth factor receptor in NSCLC cell lines. CONCLUSIONS: CD133+ CD34- is a CSC marker in H1650. miR-27a is highly expressed in H1650 CSCs and regulates cancer development in H1650. miR-27a may be a potential target for NSCLC therapy.